FNY Managed Accounts’s Idexx Laboratories IDXX Stock Holding History

FNY Managed Accounts’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-93	Closed	-$14K	–	378
2017 Q1	$14K	Buy	+93	New	+$12.8K	0.04%	429

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

FNY Managed Accounts's IDXX Position: Q2 2017 in Review

FNY Managed Accounts sold out of Idexx Laboratories (IDXX) in Q2 2017, closing a stake of 93 shares — an estimated $14K sold.

FNY Managed Accounts first reported a position in IDXX in Q1 2017 and held it in 1 quarter. The position peaked at $14K in Q1 2017. 582 funds tracked by Wall St. Rank hold IDXX as of Q2 2017.

FNY Managed Accounts reported no remaining Idexx Laboratories position as of Q2 2017 after selling out during the quarter.
FNY Managed Accounts sold 93 Idexx Laboratories shares in Q2 2017, an estimated $14K.
FNY Managed Accounts first reported a position in Idexx Laboratories in Q1 2017 and held it in 1 quarter.
FNY Managed Accounts's Idexx Laboratories position peaked at $14K in Q1 2017.
582 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.